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Introduction
Spinal muscular atrophy (SMA) is one of a wide spectrum
of muscle and nerve disorders that affect infants and
young children. Statistically, it is one of the most common
genetic diseases leading to death in childhood, and it
represents the second most common fatal autosomal
recessive disorder with an overall incidence of 1 in
10,000 live births and a carrier frequency of 1 in 35 to
1 in 50 [1–4]. Despite establishment of SMA registries
in various ethnic groups, there is still a lack of epidemio-
logic SMA data in Taiwan.
Patients who are referred for molecular genetic
testing generally have symptoms including hypo-
tonia, floppiness, proximal muscle weakness, and
loss of ambulation. Clinical symptoms among many
neuromuscular disorders are overlapping and may not
be sufficiently specific to make a reliable clinical diagnosis
of SMA. In the past, many affected patients died without
proper clinical diagnosis due to limited facilities and
lack of awareness in primary care providers. In such
circumstances, molecular genetic testing for SMA is the
best method to confirm the clinical diagnosis. Improved
diagnostic techniques to identify patients with SMA
show that the prevalence of SMA is still underestimated.
Clinical Features
SMA is characterized by the degeneration of motor
neurons in the anterior horn cells of the spinal cord and
brain stem nuclei [4,5], resulting in progressive symmetric
muscular weakness and atrophy. Children with SMA
have general intelligence in the normal range and no
sensory loss. Using the International SMA Consortium
classification, different subtypes of this common disease
are recognized, based on age at onset of symptoms,
clinical severity, achievement of milestones, and life
span (Table) [6,7].
SMA I manifests as severe weakness before 6 months
of age. Affected children are not able to sit without
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support. Proximal symmetric muscle weakness, lack of
motor development, and poor muscle tone are the
major clinical manifestations. Infants with the gravest
prognosis have problems sucking or swallowing and
often show abdominal breathing. Fasciculation of the
tongue is seen in most but not all individuals. The ocular
muscles and the diaphragm are not involved until late in
the disease course. Prognosis depends primarily on
respiratory function.
SMA II usually manifests between 6 and 12 months
of age. Although poor muscle tone may be evident at
birth or within the first few months of life, affected
individuals may gain motor milestones slowly. Finger
trembling and general flaccidity are common. These
patients, on average, lose the ability to sit independently
by their mid-teens.
Individuals with SMA III walk independently but
may fall frequently or have trouble climbing stairs,
running and jumping at age 2–3 years. The proximal
muscle weakness often occurs in the legs more than in
the arms. Prognosis generally correlates with the
maximum motor function attained. In SMA IV patients,
the onset of muscle weakness is usually in the second or
third decade of life, and clinical findings are similar to
those described for SMA III.
Despite worldwide efforts in the modern era, SMA is
incurable mainly due to its severity and because the
methods used to deliver therapeutically active molecules
are still inefficient.
Molecular Genetics
Molecular genetic analysis has mapped all three forms
of childhood and adult SMA to chromosome 5q11.2–
q13.3 [8,9]. The gene responsible for the disease has
been identified and named the survival motor neuron
(SMN) gene [10]. Genetic heterogeneity concerns about
5% of SMA patients, in whom the disease is not linked
to the 5q13 locus. The human SMN gene is located
within a duplicated region, and the two almost identical
copies of the SMN gene include telomeric SMN (SMN1;
MIM# 600354) and centromeric SMN (SMN2; MIM#
601627). The telomeric and centromeric SMN genes are
composed of nine exons (exon 2 is split into 2a and 2b)
[11]. SMA is caused by mutations or deletion of the
telomeric SMN1 gene, leading to depletion in SMN
protein levels [12,13]. SMN2 is not directly responsible
for SMA and is absent in 5% of the normal healthy
population [10].
SMN1 and SMN2 differ only in five intronic and three
exonic nucleotides [10,11], although other studies report
only five nucleotide differences between the two genes:
one in intron 6, one in exon 7, two in intron 7, and one
in exon 8 [9,14]. The two highly homologous SMN genes
differ in only two nucleotides in the coding region,
located in exons 7 and 8, allowing the SMN1 gene to be
distinguished from the SMN2 gene [10]. SMN2 fails to
compensate for the loss of SMN1 because exon 7 is
alternatively spliced, producing a truncated protein
that is unstable. SMN1 and SMN2 differ by a critical C-
to-T substitution at position 6 of exon 7 in SMN2. This
substitution alone is enough to cause an exon 7 dropout
in SMN2 (Figure 1) [15].
Genotypes in SMA patients
In most patients (~80%) with the severe SMA I phenotype,
there is a homozygous deletion of SMN1 exon 7 (and
sometimes exon 8), resulting in a defective SMN transcript
and absent protein. These patients have only the partially
functional SMN67 transcript protein from SMN2. In
most patients (~90%) with the less severe SMA II and
III phenotypes, exon 7 of SMN1 has a point mutation
resulting in the same sequence as the SMN2 exon 7,
effectively “converting” SMN1 to SMN2. The SMN1 gene
product is lost, but SMN2 gene product SMN67 is
gained, and the greater amount of SMN67 presumably
results in less severe disease [9]. Taken together with the
Table. Clinical classifications of spinal muscular atrophy (SMA) patients
Classification MIM# Severity Age of onset Clinical manifestations Prognosis
SMA I (Werdnig- 253300 Severe < 6 mo Never able to sit without support Often, death at < 2 yr old
  Hoffman disease)   due to respiratory failure
SMA II 253550 Moderate 6–18 mo Able to sit but unable to stand or Usually, death at > 2 yr old
  (intermediate)   walk unaided, variable clinical
  course
SMA III (Kugelberg- 253400 Mild > 18 mo Able to stand and walk unaided but Wheelchair-bound or
  Welander disease)   have problems with running and   death in adulthood
  jumping due to mild proximal
  weakness
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previous data, the SMN2 gene copy number is supposed
to be more critical in determining the severity of disease
than the neuronal apoptosis inhibitory protein (NAIP)
genotype [16]. SMN2 produces some full-length
transcripts and, therefore, stable SMN protein, but the
levels are reduced; for an unknown reason, this has a
particularly adverse effect on motor neurons. The number
of copies of SMN2 is clearly a modifying factor for
disease onset and severity, and the quantitative analysis
of the SMN2 gene makes it possible to predict whether
an infant with a homozygous deletion in SMN1 will
develop SMA I, II or III.
Genetic heterogeneity concerns the approximately
5–6% of patients with SMA who have at least one SMN1
exon 7 present, about half still have SMN1 mutations
and the other half may have non-5q-linked SMA.
Approximately 3% of SMA patients who are compound
heterozygotes have a deletion or gene conversion of one
copy of SMN1 and a small mutation in the other SMN1
copy [8]. Non-deletion and non-consanguineous SMA
patients should be compound heterozygous. Despite
being relatively rare, subtle mutations in SMN1 have
been shown to account for 1.8–4.8% of SMA patients
[9,10,17,18]. Mutations have been reported in all SMN1
exons except exon 5, but most are located in exon 6,
clustered in the in vitro self-oligomerization domain [13]
and in exon 3 in the Tudor domain of the SMN protein
[19,20].
Detection of the absence of SMN1 can be a useful
tool in the diagnosis of SMA. Denaturing high
performance liquid chromatography (DHPLC) analysis
with specific primers can identify SMA-affected patients
efficiently and sensitively from the SMN2-only peak. This
new method can efficiently detect homozygous SMN1
deletion/conversion in most patients. It can also
distinguish SMA compound heterozygotes with SMN1
absence in one allele and a small intragenic SMN1
mutation in the other.
Genotypes in SMA carriers
A person missing only one of their SMN genes is a
carrier and will not have SMA. However, a person who
is a carrier could have a child with SMA if their spouse
is also a carrier and the child has an affected chromo-
some from both parents. For couples who are both
SMA carriers, the risk of having a child with SMA is
approximately 1 in 4.
SMN1 copy number analysis is required to identify
carriers. The presence of the highly homologous SMN2
gene hampers detection of the loss of SMN1, which
makes detection of the gene dosage variations in the
SMA carrier test difficult. Accurate dosage analysis
is necessary to identify SMA carriers with one copy of
SMN1 from individuals with two copies of SMN1
(Figure 2).
SMN1 copy number analysis is an important
parameter to identify couples at risk for having a child
with SMA and reduces unwarranted prenatal diagnostic
tests for SMA. Thus, several different quantitative
polymerase chain reaction (PCR) tests for SMN have
been developed. These assays can determine the absolute
copy numbers of SMN1 and SMN2 to diagnose carriers
(1 SMN1/1 SMN2 or 1 SMN1/0 SMN2).
However, parents of children with SMA may not
always be carriers as there are de novo deletions in the
SMN1 gene in more than 2% of patients with SMA [21,
22]. The presence of a de novo deletion lowers the
recurrence risk for the couples from 25% to the risk of a
Figure 1. Diagrammatic representation of the genetic basis of spinal muscular atrophy (SMA) illustrating the transcripts derived
from SMN1 and SMN2 genes: SMN1 is transcribed into full length form whereas SMN2 is transcribed into 90% truncated form.
   Gene SMN2 SMN1
Exons 1...6–8 Exons 1...6–7–8 Exons 1...6–7–8
   mRNA Truncated form Full length form Full length form
90% 10% 100%
   Protein Unstable protein SMN protein SMN protein
   (abundance) + +++++
Low SMN protein results in SMA Normal SMN protein level
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second de novo mutation, which is very low. If genetic
testing shows that the affected child has two SMN gene
deletions, and one parent has two SMN gene copies and
the other parent has one SMN gene copy, further genetic
testing of the child, parents and grandparents would be
necessary to determine whether or not the child truly
has a new mutation that was not passed to the child
from a parent. However, the additional testing may
significantly lower the estimated chance of having
another child with SMA for that couple. Although new
gene deletions are uncommon, parents with one child
who has SMA may want to have carrier testing to see if
a new deletion may have occurred. Knowledge of the
carrier status of parents with affected children is useful
for determining whether a de novo mutation has occurred
and establishing the couple’s future risk of having an
affected child. If the parents are found to be carriers,
then carrier testing can be offered to the siblings of the
parents, who have a 50% risk of also being a carrier for
SMA [3].
Moreover, approximately 3–5% of carriers, referred
to as “2+0”carriers, have two copies of the SMN1 gene
on one chromosome 5 and a deletion of the SMN1 allele
on the other chromosome 5, which cannot be identified
by current carrier detection techniques (Figure 3) [23,
24].
Animal Models
To gain insight into the pathogenesis of SMA and to
understand the function of SMN inferred from the SMA
phenotype, several strategies have been used to generate
mouse models.
The first “German” model knocked out the murine
Smn gene and early embryonic lethality was observed,
Non-deletion SMN1 with point mutation (Carrier)
SMN2 SMN1
SMN2 SMN1






Figure 3. Genotypes of carriers with either a non-deletion point
mutation, one SMN1 and one SMN2, or two SMN1 copies on
one chromosome which is still difficult to identify by current
carrier-screening techniques.
Figure 2. Various representative genotypes of SMN genes in normal individuals, spinal muscular atrophy carriers, and patients.
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which may be explained by the absence of duplication of
the murine Smn gene, leading to a complete lack of SMN
protein [25,26].
A second “Taiwan” model was based on the pro-
duction of two mouse lines, one carrying a deletion of
Smn exon 7 through homologous recombination, and
the other expressing the human SMN2 gene after
microinjection of a genomic DNA fragment [27]. Mice
carrying both homozygous deletion of Smn exon 7 and
the human genomic transgene developed a variety of
symptoms including lower body weight, short and
enlarged tails, edema, chronic necrosis of the tail and
hind limbs, and a variable age of survival in littermates.
Mice with the most severe form (called type 1) died
before reaching 10 days old. Intermediate phenotype
(classified type 2) was characterized by poor activity
and death within 4 weeks of age. Mutant mice (called
type 3) survived normally but were characterized by
short and enlarged tails. The different phenotypes
observed within littermates have been correlated with
the SMN2 transgene copy number, although this remains
to be further documented.
The “American” model created mouse lines carrying
transgenic human SMN2 without the neighboring genes
[28]. The investigators selected lines containing either
low or high copy numbers of the SMN2 transgene. Mice
carrying a low copy number and harboring a homozygous
null Smn allele (Smn –/–) developed a severe phenotype
leading to death either in utero or in the first 6 hours after
birth, or survival up to 6 days of age. The absence of an
abnormal phenotype in mutant mice carrying a high
copy number of the SMN2 transgene confirmed that
SMN2 was able to rescue the embryonic lethality of the
Smn knockout mice, and demonstrated that an increased
copy number of SMN2 reduced the severity of the
phenotype, consistent with data observed in human
SMA.
The “French” model used the Cre/loxP recombination
system [29,30]. Cre-mediated deletion of Smn exon 7
directed to neurons was achieved by crossing SmnF7
mice with a transgenic mouse line expressing Cre
recombinase in neurons (“neuronal mutant”) [30].
Neuronal mutant mice displayed a severe motor defect
associated with tremors from 2 weeks of age, leading to
complete paralysis and death at a mean age of 4 weeks.
This approach was therefore able to produce mice with
a motor defect related to a muscle denervation process
of neurogenic origin, a constant feature found in human
SMA [31]. These data demonstrated that an Smn gene
defect directed to neurons but not to skeletal muscle
leads to an SMA phenotype.
Fine characterization of the neuromuscular system
of mutant mice will be very helpful to validate these
mutant mice as animal models for human SMA. The
“Taiwan” or “American” mutant mice represent valuable
genetic models of human SMA by mimicking the hu-
man genetic complexity. However, the variability in
phenotypes of mutant mice within the same litter or the
early postnatal death of mutant mice may make certain
investigations, including therapeutic trials, more difficult.
For further investigations, including therapeutic trials,
the less-severe disease phenotype makes these mutant
mice easier to use than previous models [32].
Molecular Diagnostics
The first genetic diagnosis of SMA was by linkage analysis.
Informative linkage markers have been reported from
centromeric to telomeric. Although linkage analysis is a
rapid and cost-effective method, it is an indirect
diagnostic tool. So far, a number of different tools have
been available for diagnosis of SMA. All recognize the
difference in nucleotides in exons 7 and 8 of the SMN1
and SMN2 genes and detect the absence of SMN1.
Single-strand conformation polymorphism analysis is
a simple method to detect intragenic mutations and
inconsequential polymorphism [10]. It has been largely
replaced by PCR-restriction fragment length poly-
morphism due to its low sensitivity. To measure gene
copy number for the SMN1 and SMN2 genes, restriction
enzyme digestion analysis is a simple and common
method in clinical practice [17,33]. However, it cannot
distinguish carriers with one copy of SMN1 and normal
individuals with two copies; a clear distinction between
carriers and non-carriers has not always been achieved.
SMN gene dosage analysis is necessary to identify
SMA carriers. Several diagnostic applications with
quantitative competitive PCR assays have been
developed, including fluorescence-labeled primers with
quantitative competitive PCR and real-time quantitative
PCR [2,17,21,34–37]. These methods can directly
analyze SMN1 and SMN2 gene copy numbers. However,
the disadvantages are that fluorescence-labeled probes
and a relatively expensive kit are required. Recently,
rapid multiplex PCR coupled with DHPLC methods to
detect the homozygous absence of SMN1 exon 7 and
carrier screening have been described [38].
Genetic Counseling and Risk Assessment
Only individuals with the milder forms of SMA are likely
to reproduce. The unrelated partner of an individual
with a mild form of SMA should be offered carrier
testing. If the partner shows at least two SMN1 copies,
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the partner has a 1 in 670 probability of being a carrier
(taking into consideration the 2% frequency of two
SMN1 copies on the same chromosome and the small
risk of an intragenic SMN1 mutation). Thus, their risk of
having an affected child is 1 in 1,340.
Approximately 98% of parents with an affected child
are heterozygotes with one disease-causing mutation.
The remaining parents are not carriers as their child has
a de novo disease-causing mutation, most of which are
paternal in origin [39]. According to the pattern of auto-
somal recessive inheritance, the siblings of an affected
individual have a 25% chance of being affected, a 50%
chance of being carriers, and a 25% chance of being
unaffected. If the couple are the parents of a child with
SMA, it would be predicted that a fetus with the same
genotype (i.e. molecular genetic test result) as a
previously affected sibling would have similar clinical
findings. Even if a child with SMA appears to have
inherited one disease-causing allele from a carrier parent
and to have a de novo mutation resulting in the other
disease-causing mutation, germline mosaicism in the
parent without an identifiable mutation needs to be
considered [40]; therefore, it is reasonable to consider
such a couple to have increased risk of recurrence and to
offer prenatal testing. Once an at-risk sibling is known
to be unaffected, the risk of the sibling being a carrier is
2 in 3.
If both parents are found to be carriers, the diagnosis
of SMA in the proband is most likely, and prenatal
testing can be offered. If only one parent is heterozygous,
testing of additional family members of the parent with
two SMN1 gene copies may be informative. If both
parents show at least two SMN1 copies, it is extremely
unlikely that the affected child has SMA caused by
mutations at the SMN locus.
Carrier Screening Program
Due to the high carrier frequency in the general
population, the burden of this genetic disorder is very
heavy and genetic counseling is an active component in
disease management. Owing to the homogeneity of the
molecular defect, secondary prophylaxis can readily be
offered to families at risk of SMA. In the past, SMA
carrier testing has been performed for suspected SMA
patients and parents of children clinically suspected to
have SMA.
Carriers are asymptomatic and couples who are
both carriers run a 25% risk of having an affected child
with each pregnancy. In the current medical system, we
can only identify couples at risk when they have already
borne a child with SMA. A powerful and efficient carrier-
screening program in the community would be helpful
to identify those at risk. A conditional probability of a
carrier individual having two copies of SMN1 or a point
mutation is 5%, and then two copies of SMN1 in an
individual from the general population would decrease
the probability of carrier status from 1 in 50 to 1 in 900–
1,000 [3,24]. Therefore, in spite of the fact that a
normal dosage significantly reduces the risk of being a
carrier, our results show that there is still a small risk of
recurrence [38].
Conclusion
Autosomal recessive SMA shows substantial phenotypic
variability, presenting at a variety of ages from infancy to
adult. Clinical diagnostic difficulties may arise because
SMA sometimes produces a dystrophic or myopathic
phenotype rather than classical neurogenic abnor-
malities. Intrafamilial phenotypic variation in SMA is
rare, but previous reports have described differences
in severity within the same family [41,42]. In addition,
there is currently no effective treatment or cure for SMA.
With accurate SMA genetic diagnosis, rehabilitation
and proper management of medical complications have
improved both the quality and duration of life for
affected children.
In the general population, the carrier rate for
deletional SMA is about 2%, and the incidence of SMA
is approximately 1 in 10,000. With an annual birth rate
of 150,000 in Taiwan, the expected number of SMA
births is 15, and the number of pregnancies at risk is
60. In light of this observation, it is critical to develop a
method to screen for SMA carriers in the Taiwanese
population. Recently, we introduced the detection of
SMN1 copy number in antenatal screening for carriers
and prenatal testing by DHPLC. This is an easy and
inexpensive technique for SMA carrier screening. The
cost-effectiveness would be greatly enhanced in those
with a family history of the disease. In addition, we
expect the cost would be less than the annual cost of
treatment and maintenance of an affected child on a
respirator.
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